SAN DIEGO, May 8 /PRNewswire-FirstCall/ -- Orexigen(R) Therapeutics, Inc. (Nasdaq: OREX), a biopharmaceutical company focused on the treatment of obesity, today announced that the Company will be speaking at the following investor conferences:
Bank of America and Merrill Lynch 2009 Health Care Conference
Date: Tuesday, May 12, 2009 Time: 2:40 p.m. - 3:10 p.m. Eastern Location: The New York Palace Hotel, New York Speaker: Michael Narachi, Chief Executive Officer
Canaccord Adams Diabetes and Obesity Conference
Date: Tuesday, May 12, 2009 Time: 10:40 a.m. - 11:10 a.m. Eastern Location: InterContinental The Barclay New York, New York Speaker: Graham Cooper, Chief Financial Officer
About Orexigen Therapeutics
Orexigen Therapeutics, Inc. is a biopharmaceutical company focused on the treatment of obesity. The Company's lead combination product candidates are Contrave(R), which is in Phase 3 clinical trials, and Empatic(TM), which is in the later stages of Phase 2 clinical development. Each product candidate is designed to act on a specific group of neurons in the central nervous system with the goal of achieving appetite suppression and sustained weight loss. Further information about the company can be found at http://www.orexigen.com.
|SOURCE Orexigen Therapeutics, Inc.|
Copyright©2009 PR Newswire.
All rights reserved